frank
Lv1
85 积分
2021-08-20 加入
-
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
26天前
已完结
-
重视胆囊癌的临床和基础研究
1个月前
已关闭
-
Combination locoregional and systemic therapies in hepatocellular carcinoma
2个月前
已完结
-
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
3个月前
已完结
-
Personalized MRD Assessment in Peri-surgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma
3个月前
已完结
-
Hepatic arterial infusion chemotherapy (HAIC) combined with Tislelizumab and Lenvatinib for unresectable hepatocellular carcinoma: a retrospective single-arm study
3个月前
已完结
-
Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor
4个月前
已完结
-
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
4个月前
已完结
-
原发性肝癌转化及围手术期治疗中国专家共识(2024版)
5个月前
已完结
-
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
5个月前
已完结